Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. - sprookjes - yvandenbroek - TriplyDB

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.

http://www.wikidata.org/entity/Q30491274

about

Spanning the genomics era: the vital role of a single institution biorepository for childhood cancer research over a decade Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies Identification of single- and multiple-class specific signature genes from gene expression profiles by group marker index Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma Understanding the Interplay between Expression, Mutation and Activity of ALK Receptor in Rhabdomyosarcoma Cells for Clinical Application of Small-Molecule Inhibitors Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?The receptor tyrosine kinase FGFR4 negatively regulates NF-kappaB signaling.Pediatric Rhabdomyosarcoma.Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study Artificial neural network inference (ANNI): a study on gene-gene interaction for biomarkers in childhood sarcomas.The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer.Animal models of soft-tissue sarcoma.Phage displayed peptides/antibodies recognizing growth factors and their tyrosine kinase receptors as tools for anti-cancer therapeutics.Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer Initial solid tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric preclinical testing program.The Fibroblast Growth Factor signaling pathway A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.Pitfalls in experimental designs for characterizing the transcriptional, methylational and copy number changes of oncogenes and tumor suppressor genes.FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.Clonality and evolutionary history of rhabdomyosarcoma Challenging issues in pediatric oncology The prognostic significance of fibroblast growth factor receptor 4 in non-small-cell lung cancer.MURC/cavin-4 Is Co-Expressed with Caveolin-3 in Rhabdomyosarcoma Tumors and Its Silencing Prevents Myogenic Differentiation in the Human Embryonal RD Cell Line.Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.The Effect of Mutations on Drug Sensitivity and Kinase Activity of Fibroblast Growth Factor Receptors: A Combined Experimental and Theoretical Study.Childhood rhabdomyosarcoma: recent advances and prospective views.Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma.Apoptosis resistance and PKC signaling: distinguishing features of high and low metastatic cells.Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response

P2860

Q26770333-6C19EB4F-11B2-440B-A9A8-535364B74A34 Q26801718-B56DFF28-13BD-4BF7-B26A-D75B7B08198F Q26825000-06C3EAD3-6E20-4B73-8CDF-850CEDF2FCC5 Q26998790-0772CCB0-4DB1-49E4-9D5B-BFAA43210890 Q26998955-3A59D0FB-9665-4DCB-9A4D-B4C79B876AB5 Q27853244-232EE009-DCC4-4229-AE06-1A8309946904 Q28079232-57182C8C-E406-406F-A2CE-70A778AC5F26 Q28476766-BB5188B5-0D96-4676-89B7-1ACB36C6FDD3 Q28485302-C893CA58-C63D-4459-842B-AF7FF9C85A1F Q28546245-3E68CCC6-EEBC-41B5-AF10-9A3CC008CE45 Q33751398-0281B6A9-061B-453A-9F14-8CE5498F886D Q33784827-56E2B3B9-0223-4AD0-8AE1-486FC3ECF2A1 Q33842070-3C5469E8-3AF7-424A-B9C3-2C6E0FE6A1C6 Q33885479-BB4A6CEA-401E-4A8A-9740-F4DF8FE801ED Q33904902-E68D2810-B5D4-422C-BD54-8C2CFB483878 Q33993529-1C2237FF-1910-4D73-AA88-0EAAD0C50E2B Q34069048-4F5A7D33-1F09-46EE-9893-31D2A4BE66A6 Q34098113-431D6BF0-2EEB-46B5-B9E7-D58279B4E69A Q34273411-BAD67038-25F9-4CFA-BEB5-A7297375BD20 Q34358404-0B6C67A9-4DEE-41A6-B410-711513545869 Q34361391-B62BFA0A-BFEA-4456-8D7F-761EF883A24D Q34467171-7A152984-D07F-4E5F-B1C1-92CF98871274 Q34507108-F11ABF0F-0D8F-43F7-AD72-5D2B30D46BA2 Q34525925-30DA0706-EF9E-4F77-B1EF-36FF7933E58B Q34614747-4581D007-202E-4D4D-B677-AD61E9A5C3CA Q34733972-3BE7D2EB-6A90-4188-90E4-B299F755BE2D Q34992813-4EBC9FAF-2DE2-4F3F-B10B-C4257744A973 Q35017004-A7C8502F-BD91-4EF0-BAA9-7573FEC96BA2 Q35096201-BEB0802A-D9D1-4A77-B8FB-E469F5899B8A Q35175269-9203E00A-0B84-4E2A-8CBE-192584586681 Q35602419-1D3C02FF-D42F-47DD-B011-A911B6D5B529 Q35659865-27F7FF57-736E-4B7C-8169-7746601B5041 Q35667137-89C29D72-39FB-447B-B7FE-A3A2F24ED163 Q35711420-F1AB3F93-A535-4DCC-9909-FEF209A7F7AA Q35729391-EC76D19A-DD54-4A38-8D0B-C26314A328C5 Q35752926-6FEDE178-A78E-400D-880F-F1FBCEC100E7 Q35847829-0B2138B1-A716-4383-B0C7-2DA23823400F Q35863493-2EEEA96C-2984-4B63-BC52-32E368FE52AB Q35882212-8FB18E80-21F8-4FA2-8210-37BFE58B5207 Q35929495-27031420-56AF-4FF5-95E1-C0874F61712A

P2860

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.

http://www.wikidata.org/entity/Q30491274

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Identification of FGFR4-activa ...... is in xenotransplanted models.

@ast

Identification of FGFR4-activa ...... is in xenotransplanted models.

@en

type

label

Identification of FGFR4-activa ...... is in xenotransplanted models.

@ast

Identification of FGFR4-activa ...... is in xenotransplanted models.

@en

prefLabel

Identification of FGFR4-activa ...... is in xenotransplanted models.

@ast

Identification of FGFR4-activa ...... is in xenotransplanted models.

@en

P1433

Q30491274-5FCF3AD8-2001-4AA8-B8BB-EFF475C9DB12

P1476

Q30491274-5A407050-F861-4DBD-B864-59A45BD54C29

P2093

Q30491274-076FCF84-C7E3-49B1-A444-25AA822A3292

Q30491274-0B6E8C28-21F9-4655-8AF5-1561410DF33E

Q30491274-1353202C-93B8-4B63-96DE-10325ED8630C

Q30491274-18688D3A-41FC-4A66-BF43-175DF26EB37D

Q30491274-1FE7947C-FCF2-4A76-BC31-B10A35E4EC67

Q30491274-40E442C3-38E0-4D89-8643-E375BB410B24

Q30491274-4A1352E7-801C-4B21-917B-8B3278F1E256

Q30491274-537647F5-0A9B-47BB-8184-AD8FE248B55B

Q30491274-69BC6084-E1A0-4BE9-869E-02FE46ADE507

Q30491274-799A9A04-A91E-4244-AA4E-3F24690E86F1

P2860

Q30491274-067831AF-4004-422C-80CB-7CBCA1C85809

Q30491274-0AC4CB55-1584-4DB7-AE88-077FD821A84B

Q30491274-0F8B2251-0187-44E4-A399-CC3F3E3F86EB

Q30491274-17137B34-0522-4638-B1A8-E9EC05C778A6

Q30491274-1ABD6154-4536-4482-9FAE-D3A033854FE0

Q30491274-20C6D406-1421-406D-9AEA-917276F51842

Q30491274-2106752F-9BF9-4CAE-A078-853F414E0F8D

Q30491274-24F87FDD-3F56-435C-A081-4BFF8E61E876

Q30491274-28439397-590E-4BD4-A68C-84DBF37B9F4E

Q30491274-28E52AEE-48CA-4C86-A59C-32ECB14734C4

P304

Q30491274-D6802F1A-00A0-466E-9456-EFD805515646

P31

Q30491274-6EAF1044-ECAC-4D13-8B0B-9E4D4E05EB67

P356

Q30491274-DA6CE7B7-9449-468C-B5B8-C87F04330237

P407

Q30491274-8E4C0E27-A365-4719-9CB4-CD4B4AC945A9

P433

Q30491274-3D3663DB-874A-4A13-80BB-3E4E6F510E39

P478

Q30491274-F677F0CD-32A5-43DA-9A12-B886E0D0FC4E

P50

Q30491274-0656E8F2-F84B-40E5-BFA0-838D819799E9

Q30491274-219759AE-B3DF-45D4-9603-EB2018243F52

Q30491274-540C1B52-E113-4F92-B159-6F190353193A

Q30491274-F8924BA6-0646-412C-9219-98E7C35839C4

P577

Q30491274-180CFEF9-787B-4F9C-9A78-4DF5C8F8052E

P698

Q30491274-0C35E43D-C705-4CD1-B7C5-87ACE003A245

P932

Q30491274-16B16C06-0A86-4437-A394-6201F43D1C9A

P356

P1433

Journal of Clinical Investigation

P1476

Identification of FGFR4-activa ...... is in xenotransplanted models.

@en

P2093

Adam T Cheuk

http://www.w3.org/2001/XMLSchema#string

Arnulfo Mendoza

http://www.w3.org/2001/XMLSchema#string

Chand Khanna

http://www.w3.org/2001/XMLSchema#string

Choh Yeung

http://www.w3.org/2001/XMLSchema#string

Daniel Catchpoole

http://www.w3.org/2001/XMLSchema#string

Glenn Merlino

http://www.w3.org/2001/XMLSchema#string

Javed Khan

http://www.w3.org/2001/XMLSchema#string

Jun Fang

http://www.w3.org/2001/XMLSchema#string

Jun S Wei

http://www.w3.org/2001/XMLSchema#string

Krupa Desai

http://www.w3.org/2001/XMLSchema#string

P2860

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

Cellular signaling by fibroblast growth factor receptors

The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses

Somatic mutations affect key pathways in lung adenocarcinoma

An integrated genomic analysis of human glioblastoma multiforme

Identification of ALK as a major familial neuroblastoma predisposition gene

A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases

Structural basis for reduced FGFR2 activity in LADD syndrome: Implications for FGFR autoinhibition and activation

P304

3395-3407

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI39703

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

Stephen Chanock

Stephen M. Hewitt

Joon-Yong Chung

P577

2009-10-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19809159

http://www.w3.org/2001/XMLSchema#string

P932

2769177

http://www.w3.org/2001/XMLSchema#string